{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:52:27Z","timestamp":1776336747178,"version":"3.51.2"},"reference-count":42,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Prophylaxis is the standard of care for people living with haemophilia (PwH) as it is able to prevent majority of bleeding episodes, including joint bleeds and life\u2010threatening bleeds (i.e., intracranial haemorrhage). However, despite undeniable advantages, prophylaxis has limitations including need for frequent intravenous infusions and cost. Adherence to long\u2010term treatment regimens based on multiple weekly intravenous injections of standard half\u2010life products is challenging, and it is highly likely that injections are skipped or delayed with great impact on efficacy due to the rather rapid clearance of the drug from the body. The advent of extended half\u2010life products allowed for greater flexibility and easier treatment personalization with the possibility to improve protection as well as to reduce number of intravenous injections. For people living with haemophilia A and inhibitors the advent of the first non\u2010replacement therapy, emicizumab, made a turning point offering for the first time an effective prophylaxis with the additional advantage of a consistent steady state of haemostatic effect across different ages and body weights and of subcutaneous route of administration. However, during emicizumab prophylaxis breakthrough bleeds might occur due to the limited haemostatic potential which stays in the mild haemophilia range with some interindividual variability and not clearly definable FVIII equivalence. More recently the toolbox for haemophilia care has further expanded with several non\u2010factor therapies that will offer the opportunity of effective prophylaxis to people with haemophilia B with inhibitors, subcutaneous prophylaxis for all PwH and the promise of protection in the non\u2010haemophilia range.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hae.70263","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:01:47Z","timestamp":1776333707000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expanding the Toolbox With Non\u2010Factor Therapies"],"prefix":"10.1111","author":[{"given":"Maria Elisa","family":"Mancuso","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University, Pieve Emanuele  Milan Italy"},{"name":"Center For Thrombosis and Hemorrhagic Diseases IRCCS Humanitas Research Hospital, Rozzano  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"6","key":"e_1_2_8_2_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia","volume":"26","author":"Srivastava A.","year":"2020","journal-title":"Haemophilia: The Official Journal of the World Federation of Hemophilia"},{"issue":"2","key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1651-2227.1976.tb16525.x","article-title":"Haemophilia Prophylaxis in Sweden","volume":"65","author":"Nilsson I. M.","year":"1976","journal-title":"Acta Paediatrica Scandinavica"},{"issue":"1","key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty\u2010Five Years' Experience of Prophylactic Treatment in Severe Haemophilia A and B","volume":"232","author":"Nilsson I. M.","year":"1992","journal-title":"Journal of Internal Medicine"},{"issue":"5","key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2796.1997.130135000.x","article-title":"Haemophilia Prophylaxis in Young Patients\u2013A Long\u2010term Follow\u2010up","volume":"241","author":"L\u00f6fqvist T.","year":"1997","journal-title":"Journal of Internal Medicine"},{"issue":"2","key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1111\/j.1365-2516.2007.01501.x","article-title":"Identifying and Overcoming Barriers to Prophylaxis in the Management of Haemophilia","volume":"13","author":"Petrini P.","year":"2007","journal-title":"Haemophilia: The Official Journal of the World Federation of Hemophilia"},{"issue":"3","key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00001721-199306000-00004","article-title":"Two Years' Experience With Two Recombinant Factor VIII Concentrates","volume":"4","author":"Brackmann H. H.","year":"1993","journal-title":"Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis"},{"issue":"2","key":"e_1_2_8_8_1","first-page":"S33","article-title":"Clinical Evaluation of Recombinant Factor IX","volume":"35","author":"White G.","year":"1998","journal-title":"Seminars in Hematology"},{"issue":"4","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary Prophylaxis in Severe Haemophilia Should be Started at an Early Age but Can be Individualized","volume":"105","author":"Astermark J.","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"1","key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.1365-2141.1997.3643178.x","article-title":"Complications Experienced With Central Venous Catheters in Children With Congenital Bleeding Disorders","volume":"99","author":"Collins P. W.","year":"1997","journal-title":"British Journal of Haematology"},{"issue":"2","key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/hae.13616","article-title":"Treatment Regimens and Outcomes in Severe and Moderate Haemophilia A in the UK: The THUNDER Study","volume":"25","author":"Scott M. J.","year":"2019","journal-title":"Haemophilia: The Official Journal of the World Federation of Hemophilia"},{"issue":"3","key":"e_1_2_8_12_1","first-page":"364","article-title":"Turning Severe Into Moderate Haemophilia by Prophylaxis: Are We Reaching Our Goal?","volume":"11","author":"Uijl I.","year":"2013","journal-title":"Blood Transfusion = Transfusione del Snague"},{"issue":"7","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","article-title":"Factor VIII Activity and Bleeding Risk During Prophylaxis for Severe Hemophilia A: A Population Pharmacokinetic Model","volume":"106","author":"Tiede A.","year":"2021","journal-title":"Haematologica"},{"issue":"6","key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.13360","article-title":"Role of Enhanced Half\u2010Life Factor VIII and IX in the Treatment of Haemophilia","volume":"169","author":"Mahdi A. J.","year":"2015","journal-title":"British Journal of Haematology"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101164","article-title":"Nothing Short of a Revolution: Novel Extended Half\u2010life Factor VIII Replacement Products and Non\u2010Replacement Agents Reshape the Treatment Landscape in Hemophilia A","volume":"64","author":"Abdelgawad H. A. H.","year":"2024","journal-title":"Blood Reviews"},{"issue":"9","key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A With Inhibitors","volume":"377","author":"Oldenburg J.","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"24","key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A Multicenter, Open\u2010Label Phase 3 Study of Emicizumab Prophylaxis In Children With Hemophilia A With Inhibitors","volume":"134","author":"Young G.","year":"2019","journal-title":"Blood"},{"issue":"23","key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a Bispecific Antibody Recognizing Coagulation Factors IX and X: How Does It Actually Compare to Factor VIII?","volume":"130","author":"Lenting P. J.","year":"2017","journal-title":"Blood"},{"issue":"6","key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/hae.70131","article-title":"The Mirage of Factor Equivalence: Examining the Complexities of Non\u2010Factor Therapies in Haemophilia","volume":"31","author":"Dargaud Y.","year":"2025","journal-title":"Haemophilia: The Official Journal of the World Federation of Hemophilia"},{"issue":"11","key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","article-title":"BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A","volume":"383","author":"Konkle B. A.","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 Trial of Concizumab in Hemophilia With Inhibitors","volume":"389","author":"Matsushita T.","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"e891","DOI":"10.1016\/S2352-3026(24)00307-7","article-title":"Concizumab Prophylaxis in People With Haemophilia A or Haemophilia B Without Inhibitors (explorer8): A Prospective, Multicentre, Open\u2010Label, Randomised, Phase 3a Trial","volume":"11","author":"Chowdary P.","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"14","key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.2024027468","article-title":"Marstacimab Prophylaxis in Hemophilia A\/B Without Inhibitors: Results From the Phase 3 BASIS Trial","volume":"146","author":"Matino D.","year":"2025","journal-title":"Blood"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood.2025031065","article-title":"Efficacy and Safety of Marstacimab Prophylaxis in Hemophilia A\/B with Inhibitors: Results From the Phase 3 BASIS Trial","volume":"147","author":"Matino D.","year":"2025","journal-title":"Blood"},{"issue":"5","key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran Prophylaxis in People With Severe Haemophilia A or Haemophilia B Without Inhibitors (ATLAS\u2010A\/B): A Multicentre, Open\u2010Label, Randomised, Phase 3 Trial","volume":"10","author":"Srivastava A.","year":"2023","journal-title":"The Lancet Haematology"},{"issue":"10386","key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and Safety of Fitusiran Prophylaxis in People With Haemophilia A or Haemophilia B With Inhibitors (ATLAS\u2010INH): A Multicentre, Open\u2010Label, Randomised Phase 3 Trial","volume":"401","author":"Young G.","year":"2023","journal-title":"Lancet"},{"issue":"25","key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.2024027008","article-title":"Safety and Efficacy of a Fitusiran Antithrombin\u2010Based Dose Regimen in People With Hemophilia A or B: The ATLAS\u2010OLE Study","volume":"145","author":"Young G.","year":"2025","journal-title":"Blood"},{"issue":"4","key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtha.2023.12.016","article-title":"FRONTIER1: A Partially Randomized Phase 2 Study Assessing the Safety, Pharmacokinetics, and Pharmacodynamics of Mim8, a Factor VIIIa Mimetic","volume":"22","author":"Lentz S. R.","year":"2024","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"7","key":"e_1_2_8_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103207","article-title":"FRONTIER1 multiple Ascending Dose Extension: A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Mim8 in People With Hemophilia A","volume":"9","author":"Chowdary P.","year":"2025","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"1","key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"S537","DOI":"10.1182\/blood-2025-537","article-title":"Mim8 Prophylaxis in Adults and Adolescents With Hemophilia A: 52\u2010Week Efficacy and Safety Outcomes From the Phase 3 FRONTIER2 Study","volume":"146","author":"Lentz S.","year":"2025","journal-title":"Blood"},{"issue":"2","key":"e_1_2_8_31_1","first-page":"S244","article-title":"FRONTIER5 Direct Switch Study: Safety of Initiating Mim8 Prophylaxis Without Washout of Emicizumab","volume":"9","author":"Oldenburg J.","year":"2025","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"2","key":"e_1_2_8_32_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtha.2023.09.034","article-title":"A Bispecific Antibody NXT007 Exerts a Hemostatic Activity in Hemophilia A Monkeys Enough to Keep a Nonhemophilic State","volume":"22","author":"Teranishi\u2010Ikawa Y.","year":"2024","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"issue":"2","key":"e_1_2_8_33_1","first-page":"S243","article-title":"NXT007 Prophylaxis in Emicizumab\u2010Naive Persons With Hemophilia A Without Inhibitor: Phase I\/II Study","volume":"9","author":"Shima M.","year":"2025","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"1","key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1182\/blood-2025-302","article-title":"NXT007 Prophylaxis in People With Hemophilia A With or Without FVIII Inhibitors: A Global Phase I\/II Multiple\u2010Ascending\u2010Dose Study","volume":"146","author":"Mancuso M. E.","year":"2025","journal-title":"Blood"},{"issue":"6","key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/jth.15697","article-title":"Regulation of Coagulation by Tissue Factor Pathway Inhibitor: Implications for Hemophilia Therapy","volume":"20","author":"Mast A. E.","year":"2022","journal-title":"Journal of Thrombosis and Haemostasis: JTH"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102476","article-title":"Concizumab Prophylaxis in Persons With Hemophilia A or B With Inhibitors: Patient\u2010Reported Outcome Results From the Phase 3 Explorer7 Study","volume":"8","author":"Tran H.","year":"2024","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"key":"e_1_2_8_37_1","unstructured":"European Medicines Agency \u201cAlhemo \u201dhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alhemo."},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018264"},{"key":"e_1_2_8_39_1","unstructured":"European Medicines Agency \u201cHympavzi \u201dhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hympavzi."},{"issue":"2","key":"e_1_2_8_40_1","first-page":"S241","article-title":"Long\u2010Term Efficacy of Marstacimab in Participants With Severe Hemophilia A or B Without Inhibitors","volume":"9","author":"Matino D.","year":"2025","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"8","key":"e_1_2_8_41_1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s40265-025-02203-y","article-title":"Fitusiran: First Approval","volume":"85","author":"Lee A.","year":"2025","journal-title":"Drugs"},{"issue":"4","key":"e_1_2_8_42_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin Lowering in Hemophilia: A Closer Look at Fitusiran","volume":"7","author":"Young G.","year":"2023","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"14","key":"e_1_2_8_43_1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab Prophylaxis in Infants With Hemophilia A (HAVEN 7): Primary Analysis of a Phase 3b Open\u2010Label Trial","volume":"143","author":"Pipe S. W.","year":"2024","journal-title":"Blood"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70263","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.70263","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.70263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:01:53Z","timestamp":1776333713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.70263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":42,"alternative-id":["10.1111\/hae.70263"],"URL":"https:\/\/doi.org\/10.1111\/hae.70263","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"2025-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"hae.70263"}}